TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7162-7167

  Kinde, Isaac ^a   Munari, Enrico ^c   Faraj, Sheila F ^c   Hruban, Ralph H ^c,d   Schoenberg, Mark ^d   Bivalacqua, Trinity ^d   Allaf, Mohamad ^d   Springer, Simeon ^a   Wang, Yuxuan ^a   Diaz Jr , Luis A ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a,b   Papadopoulos, Nickolas ^a   Netto, George J ^c,d  

^a Ludwig Center for Cancer Genetics and Therapeutics   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; TERT GENE; TRANSITIONAL CELL CARCINOMA; URINALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84891274034     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-2498     Document Type: Article

References (17)

1. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Netto GJ. Clinical applications of recent molecular advances in urologic malignancies: No longer chasing a "mirage" Adv Anat Pathol 2013;20:175-203.
3. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and meta-analyses. Urology 2003;61: 109-18.
4. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003;92:911-4.
5. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61.
6. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9.
7. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013;110:6021-6.
8. Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 2011;108:9530-5.
9. Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IeM, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013;5:167ra4.
10. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: Prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002;55:900-5.
11. Herr HW, Donat SM, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178:1201-5.
12. Miyamoto H, Brimo F, Schultz L, Ye H, Miller JS, Fajardo DA, et al. Low-grade papillary urothelial carcinoma of the urinary bladder: A clinicopathologic analysis of a post-World Health Organization/ International Society of Urological Pathology classification cohort from a single academic center. Arch Pathol Lab Med 2010;134: 1160-3.
13. Chaux A, Karram S, Miller JS, Fajardo DA, Lee TK, Miyamoto H, et al. High-grade papillary urothelial carcinoma of the urinary tract: A clinicopathologic analysis of a post-World Health Organization/International Society of Urological Pathology classification cohort from a single academic center. Hum Pathol 2012;43:115-20.
14. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 2013;339: 1546-58.
15. WuXR. Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 2005;5:713-25.
16. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
17. Eble JN, Sauter G, Epstein JI. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, France: International Agency for Research on Cancer Press; 2004.